BlossomHill Therapeutics (NASDAQ:BLSM) Trading Down 7.2% - Here's What Happened

Key Points

• BlossomHill Therapeutics shares fell 7.2% to $23.43, while trading volume dropped 83% below the average daily level.
• Analysts remain broadly positive, with five Buy ratings and one Hold rating producing a “Moderate Buy” consensus and an average price target of $35.00.
• The company reported quarterly EPS of -$8.75, missing the consensus estimate by $7.91, although insiders purchased 1.57 million shares worth approximately $25.2 million over the past 90 days.

BlossomHill Therapeutics, Inc. (NASDAQ:BLSM - Get Free Report) dropped 7.2% during trading on Wednesday . The stock traded as low as $23.43 and last traded at $23.43. Approximately 38,369 shares were traded during trading, a decline of 83% from the average daily volume of 223,226 shares. The stock had previously closed at $25.25.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on BLSM shares. Wall Street Zen upgraded shares of BlossomHill Therapeutics to a "hold" rating in a research report on Saturday, August 15th. JPMorgan Chase & Co. began coverage on shares of BlossomHill Therapeutics in a research report on Tuesday, September 1st. They issued an "overweight" rating and a $28.00 price objective on the stock. Lifesci Capital began coverage on BlossomHill Therapeutics in a research note on Tuesday, September 1st. They set an "outperform" rating and a $32.00 target price on the stock. Guggenheim increased their price target on BlossomHill Therapeutics from $30.00 to $40.00 and gave the stock a "buy" rating in a report on Monday. Finally, HC Wainwright assumed coverage on BlossomHill Therapeutics in a research note on Tuesday, September 1st. They set a "buy" rating and a $35.00 price target for the company. Five research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $35.00.

BlossomHill Therapeutics Trading Down 9.7%

BlossomHill Therapeutics (NASDAQ:BLSM - Get Free Report) last released its quarterly earnings results on Friday, September 18th. The company reported ($8.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($7.91). As a group, equities analysts forecast that BlossomHill Therapeutics, Inc. will post -3.86 EPS for the current fiscal year.

Insider Transactions at BlossomHill Therapeutics

In other BlossomHill Therapeutics news, Director John P. Schmid purchased 6,000 shares of the stock in a transaction on Monday, August 10th. The shares were bought at an average cost of $16.00 per share, with a total value of $96,000.00. Following the completion of the acquisition, the director owned 6,000 shares in the company, valued at $96,000. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Carl L. Gordon purchased 625,000 shares of BlossomHill Therapeutics stock in a transaction that occurred on Monday, August 10th. The shares were bought at an average price of $16.00 per share, with a total value of $10,000,000.00. Following the completion of the transaction, the director owned 2,714,279 shares of the company's stock, valued at $43,428,464. This represents a 29.91% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders acquired 1,573,900 shares of company stock worth $25,181,900 over the last 90 days.

About BlossomHill Therapeutics

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company's lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.